CogniCurrent

COGNICURRENT

Feb 2 • 18:12 UTC • 🇧🇷 Brazil • G1 (PT)

Anvisa approves the use of semaglutide for reducing cardiovascular risk

Brazil's National Health Surveillance Agency (Anvisa) has approved semaglutide for reducing the risk of cardiovascular events, a drug popularized for weight loss efficacy.

#semaglutide #cardiovascular #anvisa #brazil #weight loss
Read Original Back to Feed

📡 Similar Coverage